Co-Diagnostics, Inc. to Present Zika Tests to Dominican Republic Ministry of Health
October 16 2017 - 7:30AM
Business Wire
Co-Diagnostics, Inc. (NASDAQ: CODX) (“Co-Diagnostics” or
the “Company”), a molecular diagnostics company with a unique,
proprietary platform for the development of molecular diagnostic
tests, announced today upcoming meetings with the Ministry of
Public Health and Social Assistance (SESPAS) of the Dominican
Republic to discuss the Company’s products.
The meetings will take place the week of October 16, 2017, with
senior officials of the Centro Nacional de Control de Enfermedades
Tropicales (National Center of Control of Tropical Diseases, or
CEDCET), a division of SESPAS responsible for the prevention and
control of malaria, dengue, intestinal parasites, Schistosomiasis
(Bilharziasis), and the elimination of lymphatic filariasis for the
10.65 million residents of the Dominican Republic. Co-Diagnostics
representatives will present the both the Company’s Zika virus and
tuberculosis qPCR tests as diagnostic solutions to those diseases
in the region, and will demonstrate diagnostic equipment for which
the Company is an authorized reseller. The equipment and tests are
optimized to work together to provide complete diagnostics systems
to laboratories worldwide that are in need of upgraded facilities,
and highly accurate molecular tests and analysis at competitive
prices.
Co-Diagnostics CEO Dwight Egan commended: “Our ability to
provide diagnostics at affordable prices is the cornerstone of our
commitment to underserved populations in regions like the Dominican
Republic. Our proprietary design and technology platform allows us
to do so not only more affordably, but also via state-of-the-art
technology that represents a leap forward in the understanding of
real-time PCR molecular diagnostics, now recognized as the gold
standard in disease detection.”
About Co-Diagnostics, Inc.:Co-Diagnostics, Inc., a Utah
corporation, is a molecular diagnostics company that has developed
and intends to manufacture and sell reagents used for diagnostic
tests that function via the detection and/or analysis of nucleic
acid molecules (DNA or RNA), and to sell diagnostic equipment from
other manufacturers as self-contained lab systems.
Forward-Looking Statements:This press release contains
forward-looking statements. Forward-looking statements can be
identified by words such as "believes," "expects," "estimates,"
"intends," "may," "plans," "will" and similar expressions, or the
negative of these words. Such forward-looking statements are based
on facts and conditions as they exist at the time such statements
are made and predictions as to future facts and conditions. Readers
of this press release are cautioned not to place undue reliance on
any forward-looking statements. The Company does not undertake any
obligation to update any forward-looking statement relating to
matters discussed in this press release, except as may be required
by applicable securities laws.
Disclaimer:This news release does not constitute an offer
to sell or a solicitation of an offer to buy the securities
described herein, nor shall there be any sale of these securities
in any state or jurisdiction in which such an offer, solicitation
or sale would be unlawful prior to registration or qualification
under the securities laws of any such state or jurisdiction.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20171016005527/en/
Co-Diagnostics Investor RelationsSeth Egan,
801-438-1036s.egan@codiagnostics.cominvestors@codiagnostics.com
Co Diagnostics (NASDAQ:CODX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Co Diagnostics (NASDAQ:CODX)
Historical Stock Chart
From Apr 2023 to Apr 2024